Beste apotheek van Nederland

Study/patient
Characteristics
Clopper 1993
9 gonadotropindeificent
hypopituitary
men
Outcome
Self-reported weekly
frequency of erection
Treatment
Group
Control
Group
Relative risk
(RR) or weighted
mean difference
(WMD)
[95% CI] or
p value
7.9 (6.1) 8.2 (7.1) p value (NS)
Testosterone (oral) vs. Placebo
Haran 2005 “Are your erections less
strong?” % reporting yes
after 12 months
86% 93% p = 0.059
Cavallini 2004
95 men > 60
with symptoms
of androgen
decline
IIEF Erectile function
(range 1–30): Median
score at baseline (range)
IIEF Erectile function:
Median score at end of
therapy (6 months)
8 (5–19) 8 (5–21) NR
16 (6–29) 8 (5-21) Testosterone
p <0.01 vs.
baseline
Testosterone (oral) vs. No Treatment
Boyanov 2003
48 middle-aged
men, with type
2 diabetes,
obesity, and
symptoms of
androgen
deficiency
IIEF–5 to assess erectile
function, score at baseline
(absent-1 to severe-5)
IIEF–5 score after
treatment
(3 months)
2.25 (0.68) 2.50 (0.75) NR
1.062 (0.90) 2.25 (0.88) p <0.05
Dihydrotestosterone Gel vs. Placebo Gel
Kunelius 2002
120 men with
andropause
symptoms
Based on difficulties in
maintaining an erection
during intercourse scale,
scored from 1 (always) to
6 (never). A score of 3
indicates difficulties 50%
of the time.
3.24 (1.35) 2.81 (1.56) NA
Testosterone 50 mg Gel (T 50) vs. Testosterone 100 mg Gel (T 100) vs. Andropatch
167